Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 master protocol of novel combination therapies in unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
CTR20230169Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Mar 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of volrustomig, rilvegostomig, sonesitatug vedotin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by AstraZeneca. Started Mar 2023; status: active.
02
Drugs
volrustomigrilvegostomigsonesitatug vedotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20230169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230169.